Southern Shuanglin Bio-Pharmacy executives complete share increase plan

Southern Shuanglin Bio-Pharmacy (SZSE:000403) announced the completion of its share increase plan by key executives and core management, initially disclosed on December 28, 2024. The plan, aimed at bolstering investor confidence and supporting the company's long-term stability, concluded on June 28, 2025. A total of 311,610 shares were purchased through secondary market transactions, amounting to a total investment of CNY 5,079,589.00, representing 0.0328% of the company’s total share capital. The company also released an announcement regarding their 16th meeting of the 10th Board of Directors on June 27, 2025. It was agreed that the company's subsidiary, Harbin Pasifeike Biological Pharmaceutical Co., Ltd., needed to have its articles of association amended, and that their scope of operation be increased to include road cargo transportation (excluding dangerous goods).